Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Migraine and Headache

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

Neurology.

Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA

doi: 10.1212/

RECOMMENDED

Migraine and Headache

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

doi: 10.1177/0333102419835459.

RECOMMENDED

Migraine and Headache

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

★ 3 Recommended by Prof. Dr Christian Kamm, Faculty Member

★ 1 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Cephalalgia.

Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T

doi: 10.1177/0333102420905321.

Migraine and Headache

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Headache

Lipton RB, Cohen JM, Bibeau K, Galic M, Seminerio MJ, Ramirez Campos V, Halker Singh RB, Ailani J

doi: 10.1111/head.13997

RECOMMENDED

Migraine and Headache

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Neurology.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK

doi: 10.1212/WNL.

Migraine and Headache

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study

Headache

Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD

doi: 10.1111/head.14138

RECOMMENDED

Migraine and Headache

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies

★ 1 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache

Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM

doi: 10.1111/head.13970

RECOMMENDED

Migraine and Headache

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

Cephalalgia.

Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D

doi: 10.1177/0333102419864132.

RECOMMENDED

Epilepsy

Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Epilepsia.

Steinhoff BJ, Patten A, Williams B, Malhotra M

doi: 10.1111/epi.16428.

Neurology · Psychiatry

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Related content

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies